BetterLife Pharma (BETRF) Non Operating Interest Expenses (2010 - 2026)
BetterLife Pharma (BETRF) posted Non Operating Interest Expenses of -$16953.7 for Q2 2026, up 17.91% on a QoQ basis from -$20651.6 in Q3 2025, and up 48.9% year-over-year from -$11386.3 in Q2 2025.
Powered by 
Analysis
BetterLife Pharma (BETRF) Non Operating Interest Expenses (2010 - 2026) Analysis & Trends
BetterLife Pharma has reported Non Operating Interest Expenses for 17 years, with the latest figure at -$16953.7 in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 48.9% year-over-year to -$16953.7 in Q2 2026; TTM through Apr 2026 was -$99147.0, a 21.49% increase from a year earlier, with the FY2026 full-year figure at -$110893.5, up 7.49% from the prior year.
- Non Operating Interest Expenses was -$16953.7 for Q2 2026 at BetterLife Pharma, up from -$20651.6 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was -$1223.9 in Q2 2023, with the low at -$33848.5 in Q3 2024.
- Average Non Operating Interest Expenses over 5 years is -$14918.9, with a median of -$11300.2 recorded in 2022.
- The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses jumped 91.62% in 2022, then tumbled 2086.53% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at -$1252.1 in 2022, then slumped by 313.26% to -$5174.3 in 2023, then sank by 497.02% to -$30891.6 in 2024, then soared by 33.15% to -$20651.6 in 2025, then increased by 17.91% to -$16953.7 in 2026.
- The last three Non Operating Interest Expenses figures came in at -$16953.7 (Q2 2026), -$20651.6 (Q3 2025), and -$33174.4 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | BetterLife Pharma | 31.61 Mn | 31.59 Mn | - | -16,953.72 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -16,953.72 |
| Jul 31, 2025 | -20,651.64 |
| Apr 30, 2025 | -33,174.42 |
| Jan 31, 2025 | -28,367.27 |
| Oct 31, 2024 | -30,891.60 |
| Jul 31, 2024 | -33,848.50 |
| Apr 30, 2024 | -26,760.19 |
| Jan 31, 2024 | -22,932.11 |
| Oct 31, 2023 | -5,174.26 |
| Jul 31, 2023 | -4,399.32 |
| Apr 30, 2023 | -1,223.87 |
| Jan 31, 2023 | -4,814.62 |
| Oct 31, 2022 | -1,252.07 |
| Jul 31, 2022 | -1,293.03 |
| Apr 30, 2022 | -1,318.56 |
| Jan 31, 2022 | -5,646.71 |
| Oct 31, 2021 | -7,587.68 |
| Jul 31, 2021 | -12,425.45 |
| Apr 30, 2021 | -15,735.03 |
| Jan 31, 2021 | 6,328.01 |